B7 homolog 3 in pancreatic cancer.
| Autor: | Perovic D; Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Dusanovic Pjevic M; Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Perovic V; Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Grk M; Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Rasic M; Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Milickovic M; Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia 'Dr. Vukan Cupic', Belgrade 11000, Serbia.; Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Mijovic T; Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia 'Dr. Vukan Cupic', Belgrade 11000, Serbia., Rasic P; Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia 'Dr. Vukan Cupic', Belgrade 11000, Serbia. perasrv@yahoo.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of gastroenterology [World J Gastroenterol] 2024 Aug 21; Vol. 30 (31), pp. 3654-3667. |
| DOI: | 10.3748/wjg.v30.i31.3654 |
| Abstrakt: | Despite advances in cancer treatment, pancreatic cancer (PC) remains a disease with high mortality rates and poor survival outcomes. The B7 homolog 3 (B7-H3) checkpoint molecule is overexpressed among many malignant tumors, including PC, with low or absent expression in healthy tissues. By modulating various immunological and nonimmunological molecular mechanisms, B7-H3 may influence the progression of PC. However, the impact of B7-H3 on the survival of patients with PC remains a subject of debate. Still, most available scientific data recognize this molecule as a suppressive factor to antitumor immunity in PC. Furthermore, it has been demonstrated that B7-H3 stimulates the migration, invasion, and metastasis of PC cells, and enhances resistance to chemotherapy. In preclinical models of PC, B7-H3-targeting monoclonal antibodies have exerted profound antitumor effects by increasing natural killer cell-mediated antibody-dependent cellular cytotoxicity and delivering radioisotopes and cytotoxic drugs to the tumor site. Finally, PC treatment with B7-H3-targeting antibody-drug conjugates and chimeric antigen receptor T cells is being tested in clinical studies. This review provides a comprehensive analysis of all PC-related studies in the context of B7-H3 and points to deficiencies in the current data that should be overcome by future research. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|